Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series

Open Access Rheumatology : Research and Reviews. 2016;Volume 8:97-102


Journal Homepage

Journal Title: Open Access Rheumatology : Research and Reviews

ISSN: 1179-156X (Online)

Publisher: Dove Medical Press

LCC Subject Category: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML



Brown AN


Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 16 weeks


Abstract | Full Text

Alan N Brown Low Country Rheumatology, North Charleston, SC, USA Purpose: Although numerous treatment options are available for patients with psoriatic arthritis (PsA), a need for effective and tolerable treatments remains for patients with refractory disease who have failed previous therapies and continue to experience tender and/or swollen joints, pain, and disease activity. Repository corticotropin injection (RCI) is believed to produce steroidogenic, steroid-independent, anti-inflammatory, and immunomodulatory effects in patients with rheumatic disorders, such as PsA. Limited literature exists on the use of RCI in patients with refractory PsA. The objective of this case series is to provide information on the clinical features of patients with refractory PsA and their response to RCI.Patients: Nine patients treated with RCI for refractory PsA were retrospectively identified and included in the case series.Results: All the nine patients experienced at least transient improvements in their active skin and joint disease. In some patients, it was necessary to titrate the RCI to an appropriate dose. RCI was used in some patients to bridge with another PsA therapy, such as apremilast or certolizumab. RCI was well tolerated, but discontinued in three patients due to preexisting conditions (hypertension and hyperglycemia).Conclusion: RCI may be a safe and effective option for patients with refractory PsA who failed therapy with multiple previous treatments. Keywords: treatment, adrenocorticotropic hormone, psoriatic arthritis biologic failures, ­melanocortin, refractory